News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AtheroGenics (AGIX) Receives Delisting Notice From NASDAQ Global Market Due to Chapter 11 Filing


10/13/2008 9:12:03 AM

ATLANTA, GA--(Marketwire - October 10, 2008) - AtheroGenics, Inc. (NASDAQ: AGIX) today reported that it received notification from the Nasdaq Stock Market indicating that the staff of the Nasdaq Stock Market had determined, in accordance with NASDAQ Marketplace Rules 4300, 4450(f) and IM-4300, that the Company's common stock should be delisted from the Nasdaq Global Market in light of the Company's filing under Chapter 11 of the United States Bankruptcy Code. Trading in the Company's common stock on the Nasdaq Global Market will be suspended at the opening of business on October 14, 2008. The Company expects that its common stock will continue to trade on the over-the-counter market or the Pink Sheets.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES